A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
Annals of Oncology, 05/04/2012Morris MJ et al.
A 40–mg/kg loading dose followed by 20–mg/kg infusions every 3weeks is the recommended phase II dose of AGS–prostate stem cell antigen (PSCA). PSCA is a promising drug target and studies in prostate and other relevant solid tumors are planned.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.